Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 203,397 | 103,954 | 492,608 | 303,502 | 205,890 |
| Depreciation Amortization | 154,740 | 77,069 | 303,870 | 226,325 | 151,720 |
| Income taxes - deferred | -16,555 | -11,584 | -35,884 | -26,323 | -14,684 |
| Accounts receivable | -48,249 | -33,831 | -150,570 | -174,169 | -117,642 |
| Accounts payable and accrued liabilities | -24,985 | -41,313 | -2,652 | 5,979 | 31,466 |
| Other Working Capital | -143,077 | -91,944 | -152,554 | -209,445 | -143,973 |
| Other Operating Activity | 132,234 | 107,032 | 164,822 | 259,014 | 139,327 |
| Operating Cash Flow | $257,505 | $109,383 | $619,640 | $384,883 | $252,104 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -22,689 | -12,570 | -158,274 | -129,363 | -108,842 |
| PPE Investments | -174,258 | -106,875 | -324,733 | -235,709 | -163,316 |
| Net Acquisitions | -50,166 | -50,166 | -120,117 | -283,392 | -283,392 |
| Sale Of Investment | 2,943 | 1,953 | 4,549 | 3,104 | 205 |
| Other Investing Activity | -1,057 | -960 | -9,347 | -6,945 | -4,774 |
| Investing Cash Flow | $-245,227 | $-168,618 | $-607,922 | $-652,305 | $-560,119 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 281,796 | 192,500 | 2,952,430 | 2,798,665 | 2,180,511 |
| Debt Repayment | -317,049 | -157,328 | -2,932,636 | -2,524,387 | -1,856,262 |
| Common Stock Issued | 15,719 | 11,792 | 25,110 | 17,710 | 15,571 |
| Common Stock Repurchased | -23,978 | -19,012 | -38,651 | -38,492 | -38,468 |
| Other Financing Activity | -2,711 | -2,711 | -48,650 | -46,937 | -43,199 |
| Financing Cash Flow | $-46,223 | $25,241 | $-42,397 | $206,559 | $258,153 |
| Exchange Rate Effect | 1,508 | 1,671 | 25,579 | 10,726 | 10,756 |
| Beginning Cash Position | 241,214 | 241,214 | 246,314 | 246,314 | 246,314 |
| End Cash Position | 208,777 | 208,891 | 241,214 | 196,177 | 207,208 |
| Net Cash Flow | $-32,437 | $-32,323 | $-5,100 | $-50,137 | $-39,106 |
| Free Cash Flow | |||||
| Operating Cash Flow | 257,505 | 109,383 | 619,640 | 384,883 | 252,104 |
| Capital Expenditure | -174,258 | -106,875 | -324,733 | -235,709 | -163,316 |
| Free Cash Flow | 83,247 | 2,508 | 294,907 | 149,174 | 88,788 |